RT Journal Article
SR Electronic
T1 Point-of-care HbA1c Measurements in Oral Cancer and Control Patients in Hungary
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2248
OP 2254
DO 10.21873/invivo.12952
VO 36
IS 5
A1 ADAM VEGH
A1 DANIEL VEGH
A1 DOROTTYA BANYAI
A1 GABOR KAMMERHOFER
A1 ZITA BICZO
A1 BALAZS VOROS
A1 MARTA UJPAL
A1 JUAN FRANCISCO PEÑA-CARDELLES
A1 ZEHRA YONEL
A1 ARPAD JOOB-FANCSALY
A1 PETER HERMANN
A1 ZSOLT NEMETH
YR 2022
UL http://iv.iiarjournals.org/content/36/5/2248.abstract
AB Background/Aim: This study aimed to investigate the link between preoperative glycated hemoglobin (HbA1c) levels and oral cancer patients and diabetes mellitus (DM). We aimed to highlight the importance of point-of-care HbA1c measurements in oral cancer patients. Patients and Methods: A total of 214 patients were admitted to the Department of Inpatient Care at Semmelweis University’s Department of Oromaxillofacial Surgery and Stomatology between 1 September 2020 and 21 May 2021; individuals, who had undergone maxillofacial surgery under general anesthesia, were included in the study. Results: There was a significant difference between the oral cancer group and the control group in terms of smoking (p=0.009) and alcohol intake (p=0.003). There was no statistically significant difference regarding sex (p=0.132) and DM (p=0.147) between the two groups. The tumor group had an 8.52% greater prevalence of DM, which was not significant. In the oral cancer group, twenty individuals (17.69%) had a higher HbA1c level than the upper level of the optimal metabolic value (6.9%). Nine participants (8.91%) in the control group had an HbA1c value greater than 6.9%, which means that their metabolic level was poor. The oral cancer group did not have higher blood glucose levels than those of the control group. Conclusion: No direct connection between high blood glucose levels and oral cancer was found. However, point-of-care HbA1c measurement can be a diagnostic tool to detect DM in the dental office.